FDA Setting Record Approval Rate - This Stock Could Be A Gamechanger

NASDAQ Firm's Patents Could Have Huge Implications on $13B Market NASDAQ Firm's Patents Could Have Huge Implications on $13B Market                                                                                                      You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please [unsubscribe]( here. This message is from InMed Pharmaceuticals. --------------------------------------------------------------- Dear Investor, Alzheimer's disease has always been a tough challenge. In fact, just a few years ago Big Pharma all but abandoned their hopes on treating it. But 2024 is changing that. Over 134 drugs are now in development. Making a small firm with a critical patent... look like a prime buyout target. This tiny NASDAQ has developed a unique treatment. Unlike anything on the market - not a drug, but a [patented molecule](. One that's having remarkable results. Big Pharma is already paying close attention to potential future acquisitions. And with the Alzheimer's drug market set to hit $13 billion, the potential is enormous. Don't miss out on what could be a pivotal moment in medical history. [And what has potential to be the single most pivotal opportunity in the market today.]( Regards, InMed Pharmaceuticals Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of InMed Pharmaceuticals (NASDAQ: INM). The compensation consists of up to $2,000 and was received/will be received from Investing Media Solutions. This compensation should not be considered as an endorsement of the securities of adviser InMed Pharmaceuticals (NASDAQ: INM) and we are not responsible for any errors or omissions in any information provided about the securities of InMed Pharmaceuticals (NASDAQ: INM). We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 8/22/24. Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our [Privacy Policy]( or our [Legal Notices.]( [Unsubscribe]( Today's Bonus Content: [5 Stocks for a Trump Win in 2024]( (By clicking this link you agree to receive emails from Trading Tips and our affiliates. You can opt out at any time)